Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

BACKGROUND: The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposure-safety, and immunogenicity of atezolizumab in pediatric...

Descripción completa

Detalles Bibliográficos
Autores principales: Shemesh, Colby S., Chanu, Pascal, Jamsen, Kris, Wada, Russ, Rossato, Gianluca, Donaldson, Francis, Garg, Amit, Winter, Helen, Ruppel, Jane, Wang, Xin, Bruno, Rene, Jin, Jin, Girish, Sandhya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868826/
https://www.ncbi.nlm.nih.gov/pubmed/31753029
http://dx.doi.org/10.1186/s40425-019-0791-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868826/
https://www.ncbi.nlm.nih.gov/pubmed/31753029
http://dx.doi.org/10.1186/s40425-019-0791-x

Ejemplares similares